



PRESS ALERT
Nantes, February 1, 2021

XENOTHERA announces the effectiveness of XAV-19, its anti-Covid treatment, against SARS-CoV-2 variants and the acceleration of the clinical trial POLYCOR in several hospitals in France

The Nantes-based biotech [XENOTHERA](#) announced this morning the anti-variant efficacy of XAV-19, its anti-Covid-19 treatment, a polyclonal antibody directed against the SARS-CoV-2 virus. Biotech was able to confirm the blocking effect of XAV-19 against the different variants currently circulating, known as "British", "South African", "Brazilian", "Danish" and "Scottish".

XAV-19 is a treatment for patients with moderate COVID-19. It is currently assessed in a clinical trial in France (POLYCOR trial promoted by the Nantes University Hospital) and received the "National Research Priority" from the French health Ministry label in December 2020. To date, around twenty hospitals offer voluntary patients to participate in the test of XAV-19.

"This is a great news. It has been several years since XENOTHERA has identified the interest of its antibodies as a treatment against coronavirus infections, which allowed us to have the first clinical batch of XAV-19 as of May 2020. The efficacy of XAV-19 against circulating variants was likely, given the polyclonal nature of our product. The advantage of XAV-19 against variants is now proven, unlike monoclonal antibodies. We are actively preparing our production capacities in order to be able to treat sick people. As we have already recalled, vaccines and treatments are the two arms of the fight against the epidemic", declares Odile Duvaux, President of XENOTHERA.

To date, there are 15,000 SARS-CoV-2 mutations, some of which are better known for their possible impact on contagiousness or lethality. How can you hope to target effectively a target that is constantly moving? Polyclonal antibodies, less sensitive than monoclonal ones to mutations, are an asset. For example, a recent publication shows that a single mutation destroys all efficacy of the monoclonal REG-CoV2 (the so-called "Trump" antibody).

In this context, the glyco-humanized polyclonal antibodies of XENOTHERA prove to be an effective therapeutic approach to fight against the pandemic.

"Our POLYCOR clinical trial having recently been labeled a national research priority by the CAPNET inter-ministerial committee, under the control of Reacting, we are now calling on the government to support XAV-19; we recently read that French research was lagging behind on the epidemic, we believe that no, on the contrary, our company has an advantage which gives its the lead over many therapeutic alternatives, in particular coming from 'across the Atlantic (smile). As a French biotech, we need this support, in order to be able to produce hundreds of thousands of doses in the coming months. », continues Odile Duvaux.

Given the urgency of the health situation, the deployment of the POLYCOR trial is essential, and there are already 20 hospitals* out of some 40 volunteers who are participating in the trial promoted by the Nantes University Hospital. Strengthening the visibility of XAV-19 in French hospitals will make it possible to accelerate the availability of treatment to the greatest number of patients. Note that the participating hospitals are spread throughout the territory.

*** List of French hospitals participating in the POLYCOR trial (to date):**

CHU Nantes
CHU Saint Antoine - Paris
CHU Angers
CHU Croix Rousse - Lyon
CH Chambéry
CH La Roche / Yon
CHU Limoges
CH Mont-de-Marsan
CHU Caen
CH Orléans
CHU Amiens
CH Dax
CHU Reims
CH Le Mans
CH Nîmes
CH Avignon
CH La Rochelle
CH Quimper
CHU Strasbourg
CH Vannes

About XENOTHERA:

Created in 2014, XENOTHERA is a Nantes-based biotech that develops “glyco-humanized” polyclonal antibodies. Its technological platform is built on a dual expertise of genetics and immunology. The company has a comprehensive product portfolio, the first of which, LIS1, an immunosuppressant in transplantation, has been in the clinic since 2019. XENOTHERA has also been developing its treatment for coronavirus infections for several years. XAV-19 is XENOTHERA's treatment for patients at the start of hospitalization, it is based on a unique patented antibody production technology, developed and proven for several years by biotech. XENOTHERA is part of the scientific and medical environment of Pays de la Loire, and has been supported since its creation by private investors. Since its creation, the company has raised more than 23 million euros in financing for all of its products.

To find out more, please visit: www.xenothera.com

Follow XENOTHERA on social media: [LinkedIn](#) [Twitter](#)

About XAV-19:

XAV-19 is XENOTHERA's anti-COVID-19 treatment. It is an antiviral glyco-humanized polyclonal antibody that has the therapeutic effect of reducing the risk of worsening in patients with moderate forms of the disease. XAV-19 works by neutralizing the virus, reducing inflammation and limiting the risk of a cytokine storm. XAV-19 has been in clinical trial since September 2020 in several French hospitals.

About POLYCOR:

POLYCOR, sponsored by Nantes University Hospital, is a French phase II clinical trial aimed at evaluating the safety and efficacy of XAV-19, the anti-COVID19 treatment developed by XENOTHERA. The trial is scheduled to recruit 400 patients from around 40 hospitals. It is headed by Dr Benjamin Gaborit, and Professor François Raffi, from the Nantes University Hospital. POLYCOR was funded in July 2020 in the form of a COVID PSPC bringing together XENOTHERA, the Nantes University Hospital and the University of Nantes. The POLYCOR project received a total allocation of over € 8M from the General Secretariat for Investment.

Media relations:**IZsoGOOD**

Ingrid Zémor

+33 6 73 72 99 92

xenothera@izsogood.co